Lung Cancer (NSCLC) [Tissue]
This EQA has two modules: COMMON BIOMARKERS (mandatory to participate in this EQA) and NEW & EMERGING BIOMARKERS (optional to participate in this EQA) both using FFPE to test.
Sponsored by
, 
Overview
The scheme is designed to assess the analytical process (genotyping), and reporting (biological and clinical interpretation of the test result) including the overall report layout, content and clerical accuracy.
At a glance
Product Code:
02-LUNGT-27
Target/Genes:
If you are planning to participate in the Lung cancer (NSCLC) [Tissue] EQA scheme, it is MANDATORY to participate in the COMMON BIOMARKERS module which is designed to assess performance and reporting in routine Lung cancer tissue testing using commonly tested biomarkers in the EGFR, KRAS and BRAF genes.
If you are undertaking extended testing using new or emerging biomarkers in your clinical service, then you can also select the option to register for the OPTIONAL NEW and EMERGING BIOMARKERS module; the genes we include vary year on year, and may include, for example, variants in the EGFR, ERBB2, KRAS, TP53, MTAP or MET genes.
Technology:
NGS, Panel testing, PCR based, Whole exome sequencing, Whole genome sequencing
Sample Type:
FFPE
Submit Results In:
English, French, German, Italian, Spanish
Accredited:
Yes
Key Dates
28/02/2027
Jun-27
June - August 2027
December 2027 - January 2028
Sample Details
Mock clinical cases with matching human tumour tissue paraffin embedded (FFPE) and/or artificial FFPE reference materials (designed to simulate real patient samples) are provided for both the COMMON BIOMARKERS module and the NEW & EMERGING BIOMARKERS module. Five cases are provided for each EQA module. One 10um or 15um thick FFPE section per case is provided.
Samples are provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials.
Variant allele frequencies of any artificial FFPE materials have been validated using ddPCR.
There is a maximum of 2 x additional sets of samples per participant for COMMON BIOMARKERS and 3 x additional sets of samples per participant for NEW & EMERGING BIOMARKERS.
EQA Results
Participants will receive an individual report including educational advice and a scheme summary report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics which allow participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participation Information
For the COMMON BIOMARKERS EQA option, the minimum requirement is EGFR, KRAS and BRAF gene testing. For EGFR testing, laboratories can expect variants in all four Tyrosine Kinase (TK) domain exons.
For the NEW & EMERGING BIOMARKERS EQA option, the testing requirements will be detailed in the Scheme Instructions.
These samples are not suitable for an RNA-based methodology only.
Participants are expected to test samples according to their routine strategy. Submission of a .pdf clinical report is required for one case of each EQA module. The remaining cases require genotyping only. For all cases, mandatory completion of an online data collection form is also required.
This EQA is supported by an educational grant from AstraZeneca, fees are subsidised so there is a reduced cost for participants. The EQA providers acknowledge and thank AstraZeneca for this support.
Limited to a maximum of 400 participants, please register early to make sure you don’t miss out. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
Send your enquiry by submitting the form
Closes in 111 days
From £310.00
Buying is completed on the EMQN portal and needs a free EMQN account, which takes a few minutes to set up.
- ISO 17043 accredited scheme
- Submit results in 5 languages
Questions about this scheme?
Contact our team
Register Interest
Express your interest in ''.